Filing identity and reporting period
The supplied filing is Leap Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2020, filed November 12, 2020. This does not match the request metadata naming Cypherpunk Technologies Inc.; verify the intended company and filing before relying on this summary.
Leap is a clinical-stage biopharmaceutical company developing cancer therapies. DKN-01 is its lead candidate; TRX518 development was deprioritized in November 2019. Neither candidate was FDA-approved.
Financial performance and position
Amounts below are in millions of U.S. dollars unless otherwise noted.
| Metric | Q3 2020 | Q3 2019 | Nine months 2020 | Nine months 2019 |
|---|---|---|---|---|
| Revenue | 0.375 | — | 1.125 | — |
| Research and development expense | 5.369 | 5.772 | 15.322 | 18.698 |
| General and administrative expense | 2.514 | 2.151 | 7.188 | 6.481 |
| Total operating expenses | 7.883 | 7.923 | 22.510 | 25.179 |
| Net loss | 7.057 | 7.935 | 20.804 | 24.904 |
| Operating cash used | — | — | 19.969 | 21.008 |
- Revenue was license revenue recognized over time from the BeiGene agreement; Leap reported no product sales or royalty revenue. With no product sales, a meaningful product gross margin is not provided.
- Q3 loss per share was $0.09, versus $0.33 a year earlier. Nine-month loss per share was $0.58 versus $1.15; nine-month loss attributable to common stockholders was $30.878 million after preferred-stock and warrant-related dividends and a beneficial conversion feature.
- Cash and cash equivalents were $57.975 million at September 30, 2020, compared with $3.891 million at December 31, 2019. Total assets were $60.544 million and stockholders’ equity was $53.138 million.
- Current liabilities were $6.715 million, including $1.5 million of current deferred revenue. Lease liabilities totaled $0.648 million. The filing reports no borrowings or other conventional debt balance.
- Financing activities provided $73.997 million in the first nine months, principally from the June public offering ($48.5 million net) and January preferred-stock financing ($27.0 million proceeds). Cash increased $54.084 million over the period.
Changes versus comparable periods
- Nine-month net loss improved by $4.1 million, while operating expenses declined $2.669 million. Lower R&D costs—primarily from reduced TRX518 trial spending—were partly offset by higher G&A costs and increased DKN-01 spending.
- Q3 R&D expense declined $0.403 million overall: DKN-01 expense rose $1.469 million, while TRX518 expense fell $1.872 million. Q3 G&A increased $0.363 million.
- License revenue began in 2020 under the BeiGene agreement. The $3 million upfront payment is recognized over the service period; $1.125 million had been recognized through September 30, leaving $1.875 million deferred revenue.
- Shares issued and outstanding at September 30 were 59.658 million, versus 24.195 million at December 31, 2019. The June offering and conversions of preferred stock materially expanded the capital base; potential dilution also includes substantial warrants and options.
Outlook, commentary, risks, and unusual items
- Management expected cash at September 30 to fund operating expenses for at least 12 months from issuance of the financial statements. The company also expected continued operating losses and stated it had never generated positive operating cash flow.
- Management anticipated R&D spending would increase as DKN-01 development continued, subject to funding. No specific revenue, earnings, or clinical-development guidance was provided.
- BeiGene received an option to develop and commercialize DKN-01 in Asia excluding Japan, Australia, and New Zealand. Leap retained rights elsewhere and could receive up to $132 million in future option-exercise and milestone payments plus tiered royalties, contingent on milestones and sales.
- Clinical updates included first-patient dosing in the Phase 2a DisTinGuish study of DKN-01 with tislelizumab, with or without chemotherapy, and FDA Fast Track designation for the combination in a specified DKK1-high gastric/GEJ cancer setting. These are development updates, not evidence of approval or established efficacy.
- COVID-19 could disrupt trials, laboratory work, recruitment, vendors, and development timelines or raise costs. The filing says the extent and duration of effects were uncertain.
- Patent matters include an EPO decision maintaining narrowed claims for one TRX518 patent, an appeal concerning another revoked patent that remained pending, and a newly filed opposition to a further patent. The filing states no material indemnification claims or accrued liabilities.
- Unusual accounting/EPS items in 2020 included $9.399 million of beneficial-conversion-feature dividends, $0.372 million of preferred dividends, and $0.303 million related to a warrant down-round feature. The latter items increased the loss attributable to common stockholders beyond reported net loss.
- The filing’s financial statements report nine-month net loss of $20.804 million; one MD&A passage instead says $20.1 million. The financial-statement figure is the clearer reported value.
Key facts for investors to verify
- Confirm that Leap Therapeutics, rather than Cypherpunk Technologies, is the intended issuer.
- Review the terms, remaining option period, and potential milestone/royalty economics of the BeiGene agreement, including the deferred-revenue recognition schedule.
- Assess trial progress, enrollment, data quality, and regulatory requirements for DKN-01; Fast Track and Orphan Drug designations do not constitute approval.
- Evaluate cash use and runway against the stated 12-month expectation, given recurring losses and operating cash outflows.
- Review dilution from outstanding warrants, pre-funded warrants, options, and future equity financing needs.
- Follow the TRX518 patent opposition and appeal matters and the potential operational effects of COVID-19 on clinical development.